oseltamivir has been researched along with Behavior Disorders in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (34.62) | 29.6817 |
| 2010's | 16 (61.54) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Jang, SC; Kang, HR; Shin, JY | 1 |
| Fukushima, A; Okamura, M; Ono, H | 1 |
| Del Mar, C; Jones, M; Tett, SE | 1 |
| Kang, HR; Kim, WJ; Lee, EK; Shin, JY | 1 |
| Chen, R; Fang, Z; Huang, Y | 1 |
| Demakas, A; Dimbil, M; Doraiswamy, PM; Erdman, CB; Hoffman, KB | 1 |
| Wiwanitkit, V | 2 |
| Hosokawa, M; Kashii, H; Kubota, M; Morimoto, K; Nagai, A; Nagaoka, K; Ogihara, T; Takahashi, Y | 1 |
| Abe, J; Kato, Y; Kato, Z; Kinosada, Y; Nakamura, M; Nakayama, Y; Ueda, N; Umetsu, R | 1 |
| Shiro, H; Tomono, N | 1 |
| Falahee, ML; Vallerand, AH; Vantine, M | 1 |
| Hara, K; Nakajima, M; Shimakawa, S; Tamai, H; Tanabe, T | 1 |
| Sacks, S; Smith, JR | 1 |
| Suzuki, E; Tsuda, T; Yorifuji, T | 1 |
| Peng, MM; Robinson, NJ | 1 |
| Barbe, RP; Crisinel, PA; Dayer, P; Desmeules, JA; Fluss, J; Ing Lorenzini, K; Korff, CM; L'Huillier, AG; Posfay-Barbe, KM; Rebsamen, MC; Siegrist, CA | 1 |
| Bansod, S; Britschgi, M; Chu, T; Donner, B; Dutkowski, R; Koerner, A; Prinssen, EP; Rayner, CR; Sirzen-Zelenskaya, A; Thakrar, BT; Toovey, S | 1 |
| Baxter, R; Fry, AM; Greene, SK; Irving, SA; Jackson, ML; Jacobsen, SJ; Lee, GM; Li, L; Lieu, TA; Naleway, AL; Narwaney, KJ; Nordin, JD; Shay, DK | 1 |
| Doshi, P; Hama, R; Jefferson, T; Jones, M | 1 |
| Enger, C; Nordstrom, BL; Rothman, KJ; Sacks, S; Thakrar, B | 1 |
| Blumentals, WA; Song, X | 1 |
| Kato, S; Nisijima, K; Shioda, K; Yoshino, T; Yui, K | 1 |
1 review(s) available for oseltamivir and Behavior Disorders
| Article | Year |
|---|---|
Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: an updated review.
Topics: Adult; Antiviral Agents; Child; Humans; Influenza, Human; Mental Disorders; Oseltamivir | 2012 |
25 other study(ies) available for oseltamivir and Behavior Disorders
| Article | Year |
|---|---|
Association between oseltamivir use and neuropsychiatric adverse events in influenza patients: a nationwide population-based cohort study.
Topics: Adolescent; Adult; Age Factors; Aged; Antiviral Agents; Child; Child, Preschool; Cohort Studies; Databases, Factual; Female; Humans; Incidence; Infant; Infant, Newborn; Influenza, Human; Male; Mental Disorders; Middle Aged; Neurotoxicity Syndromes; Oseltamivir; Republic of Korea; Retrospective Studies; Young Adult | 2021 |
[Similarity of Clinically Significant Neuropsychiatric Adverse Reactions Listed in Package Inserts between the Anti-influenza Drugs Oseltamivir and Amantadine (Possibility Attributable to Common Pharmacological Effects)].
Topics: Amantadine; Antiviral Agents; Dopamine Agonists; Drug Labeling; Enzyme Inhibitors; Humans; Influenza, Human; Mental Disorders; Molecular Conformation; Nervous System Diseases; Neuraminidase; Nicotinic Antagonists; Oseltamivir | 2018 |
Psychiatric adverse events in oseltamivir prophylaxis trials: Novel comparative analysis using data obtained from clinical study reports.
Topics: Adolescent; Adult; Aged; Antibiotic Prophylaxis; Antiviral Agents; Data Interpretation, Statistical; Humans; Influenza, Human; Mental Disorders; Oseltamivir; Pharmacoepidemiology; Randomized Controlled Trials as Topic; Young Adult | 2018 |
Risk of neuropsychiatric adverse events associated with the use of oseltamivir: a nationwide population-based case-crossover study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Cohort Studies; Cross-Over Studies; Female; Humans; Incidence; Infant; Infant, Newborn; Influenza, Human; Male; Mental Disorders; Middle Aged; Oseltamivir; Population Health; Republic of Korea; Risk Factors; Young Adult | 2019 |
Neuropsychiatric events in an adult patient with influenza a (H3N2) treated with oseltamivir (Tamiflu): a case report.
Topics: Antiviral Agents; Female; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Mental Disorders; Middle Aged; Oseltamivir; RNA, Viral; Treatment Outcome | 2019 |
Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012.
Topics: Adverse Drug Reaction Reporting Systems; Antiviral Agents; Cross-Sectional Studies; Data Mining; Drug Approval; Humans; Mental Disorders; Oseltamivir; Product Surveillance, Postmarketing; Substance-Related Disorders; United States; United States Food and Drug Administration | 2013 |
Neuropsychiatric problems due to oseltamivir treatment in H7N9 bird flu.
Topics: Antiviral Agents; China; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Mental Disorders; Oseltamivir | 2014 |
Psychiatric symptoms during oseltamivir treatment.
Topics: Antiviral Agents; Humans; Influenza, Human; Mental Disorders; Oseltamivir; Treatment Outcome | 2015 |
Analysis of a child who developed abnormal neuropsychiatric symptoms after administration of oseltamivir: a case report.
Topics: Adolescent; Antiviral Agents; Female; Hallucinations; Humans; Influenza, Human; Memory Disorders; Mental Disorders; Oseltamivir; Sleep Initiation and Maintenance Disorders | 2015 |
Analysis of Neuropsychiatric Adverse Events in Patients Treated with Oseltamivir in Spontaneous Adverse Event Reports.
Topics: Adolescent; Adult; Antiviral Agents; Asia; Behavior; Behavioral Symptoms; Child; Female; Humans; Influenza, Human; Male; Mental Disorders; Odds Ratio; Oseltamivir; Young Adult | 2015 |
[The smaller number of influenza patients with neuropsychiatric events had taken oseltamivir beforehand].
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Cross-Sectional Studies; Enzyme Inhibitors; Female; Humans; Influenza, Human; Male; Mental Disorders; Neuraminidase; Oseltamivir | 2008 |
Neuropsychiatric concerns related to influenza treatment.
Topics: Antiviral Agents; Humans; Influenza Vaccines; Influenza, Human; Mental Disorders; Nervous System Diseases; Oseltamivir; Zanamivir | 2009 |
Oseltamivir treatment for children showing abnormal behavior during influenza virus infection.
Topics: Adolescent; Antiviral Agents; Child; Child Behavior Disorders; Child, Preschool; Disease Progression; Female; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Male; Mental Disorders; Oseltamivir; Time Factors; Treatment Outcome | 2010 |
Incidence of neuropsychiatric adverse events in influenza patients treated with oseltamivir or no antiviral treatment.
Topics: Adolescent; Adult; Age Factors; Antiviral Agents; Epidemiologic Methods; Female; Humans; Incidence; Influenza, Human; Male; Mental Disorders; Oseltamivir; United States; Young Adult | 2009 |
Oseltamivir and abnormal behaviors: true or not?
Topics: Adolescent; Antiviral Agents; Child; Cohort Studies; Contraindications; Humans; Influenza, Human; Japan; Mental Disorders; Oseltamivir; Reproducibility of Results | 2009 |
Oseltamivir: beware neuropsychological effects in young patients.
Topics: Antiviral Agents; Delirium; Hallucinations; Humans; Mental Disorders; Oseltamivir; Seizures | 2010 |
Oseltamivir and abnormal behavior.
Topics: Antiviral Agents; Follow-Up Studies; Humans; Mental Disorders; Oseltamivir; Risk Factors | 2010 |
ABCB1 polymorphisms and neuropsychiatric adverse events in oseltamivir-treated children during influenza H1N1/09 pandemia.
Topics: Adolescent; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Capillary Permeability; Child; Child, Preschool; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Mental Disorders; Oseltamivir; Pandemics; Polymorphism, Single Nucleotide | 2011 |
Risk of adverse events following oseltamivir treatment in influenza outpatients, Vaccine Safety Datalink Project, 2007-2010.
Topics: Antiviral Agents; Humans; Influenza Vaccines; Influenza, Human; Mental Disorders; Oseltamivir; Risk | 2013 |
Neuropsychiatric adverse events and oseltamivir for prophylaxis.
Topics: Antiviral Agents; Humans; Influenza, Human; Mental Disorders; Oseltamivir; Randomized Controlled Trials as Topic | 2012 |
Health outcomes among patients receiving oseltamivir.
Topics: Acetamides; Adult; Aged; Antiviral Agents; Cardiovascular Diseases; Female; Humans; Influenza, Human; Male; Mental Disorders; Middle Aged; Oseltamivir; Respiratory Tract Diseases | 2004 |
New concerns about oseltamivir.
Topics: Adolescent; Adult; Antiviral Agents; Child; Female; Humans; Japan; Male; Mental Disorders; Oseltamivir; Suicide | 2007 |
Oseltamivir: neuropsychiatric disorders.
Topics: Adolescent; Adult; Child; Child, Preschool; France; Humans; Influenza, Human; Japan; Mental Disorders; Nervous System Diseases; Oseltamivir; Suicide; United States | 2007 |
The safety of oseltamivir in patients with influenza: analysis of healthcare claims data from six influenza seasons.
Topics: Adolescent; Adult; Age Distribution; Antiviral Agents; Brain; Case-Control Studies; Central Nervous System Diseases; Child; Cohort Studies; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Incidence; Influenza, Human; Insurance, Health; Male; Mental Disorders; Middle Aged; Odds Ratio; Oseltamivir; Probability; Registries; Retrospective Studies; Severity of Illness Index; Sex Distribution | 2007 |
Oseltamivir (Tamiflu) increases dopamine levels in the rat medial prefrontal cortex.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Antiviral Agents; Dopamine; Enzyme Inhibitors; Extracellular Fluid; Homovanillic Acid; Male; Mental Disorders; Microdialysis; Oseltamivir; Prefrontal Cortex; Rats; Rats, Wistar; Serotonin; Synaptic Transmission; Up-Regulation | 2008 |